Elig.phs001365.v1.p1.1
Item
Patients were randomized to one of three chemotherapy regimens, and one-half of the patients also randomized to receive bevacizumab, based on reports of efficacy in the advanced disease setting. The three regimens were
boolean
C0034656 (UMLS CUI [1,1])
C0205449 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0796392 (UMLS CUI [1,4])
Elig.phs001365.v1.p1.2
Item
four cycles of docetaxel followed by four cycles of doxorubicin plus cyclophosphamide,
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1302181 (UMLS CUI [1,3])
C0246415 (UMLS CUI [1,4])
C0013089 (UMLS CUI [1,5])
C0010583 (UMLS CUI [1,6])
Elig.phs001365.v1.p1.3
Item
same as regimen 1, except for the addition of capecitabine to docetaxel, and
boolean
C0392920 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0671970 (UMLS CUI [1,3])
Elig.phs001365.v1.p1.4
Item
same as regimen 1, except for the addition of gemcitabine to docetaxel. Patients were stratified according to age at entry (<49 or >50 years old), clinical tumor size (2.0 to 4 cm or >4.1 cm), and hormone receptor status (estrogen receptor [ER] positive, progesterone receptor [PgR] positive, or both vs. ER and PgR negative). Eligibility criteria for NSABP B-40 included primary operable breast cancer which was diagnosed with a core needle biopsy with a palpable primary tumor at least 2.0 cm in diameter, HER2-negative, and TMN stages T1c to T3, N0 to N2a, and M0. All patients on current study provided blood samples for DNA extraction and consent for genetic testing.
boolean
C0392920 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0045093 (UMLS CUI [1,3])
C1514983 (UMLS CUI [2,1])
C0001779 (UMLS CUI [2,2])
C0475440 (UMLS CUI [2,3])
C0019929 (UMLS CUI [2,4])
C0449438 (UMLS CUI [2,5])
C1516637 (UMLS CUI [3,1])
C0205188 (UMLS CUI [3,2])
C0678222 (UMLS CUI [3,3])
C0475440 (UMLS CUI [3,4])
C2348908 (UMLS CUI [3,5])
C3258246 (UMLS CUI [3,6])
C0005834 (UMLS CUI [4,1])
C0012854 (UMLS CUI [4,2])
C0185115 (UMLS CUI [4,3])
C0021430 (UMLS CUI [4,4])
C0679560 (UMLS CUI [4,5])